Login
Camp4 Therapeutics Corp logo

Camp4 Therapeutics Corp

camp4tx.com

What Do They Do?

Develops RNA-targeting medicines for people with genetic diseases, with a focus on neurological disorders.

How Do They Make Money?

Earns revenue through research collaboration and license agreements.

FY2025 revenue

Who Are Their Customers?

Works with research partners, including GlaxoSmithKline, through discovery, collaboration and license agreements.

Do Revenues Turn Into Profits?

No. It lost $80.4M in FY2025.

Operating income, FY2025
−1502% of revenue
▲ +1% (Loss) vs FY2024 (−$53.1M, −8142%)
Net income, FY2025
−2299% of revenue
▼ −55% (Loss) vs FY2024 (−$51.8M, −7943%)
Free cash flow, FY2025
−853% of revenue
▲ +35% (Loss) vs FY2024 (−$46M, −7056%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +139%
vs $795K in Q3 FY2025
Net income
▼ −92% (Loss)
vs −$15.1M in Q3 FY2025

Who Do They Compete With?

Competes with Stoke Therapeutics, Acadia Pharmaceuticals, Praxis Precision Medicines, GondolaBio, Tevard Biosciences, Regel Therapeutics, Quiver Bioscience, Amgen, Ultragenyx Pharmaceutical, Arcturus Therapeutics Holdings, iECURE, Alnylam Pharmaceuticals, and Ionis Pharmaceuticals

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support